Business Context and Reporting Period
TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals, Inc.) filed this Form 8-K on July 24, 2024, to report the results of a Special Meeting of stockholders held on that date. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol TNFA.
Key Financial Metrics
This filing is a current report regarding corporate governance and capital structure changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes Versus Prior Period
The primary material change reported is the approval of an amendment to the Company's Certificate of Incorporation. Stockholders voted to increase the number of authorized shares of Common Stock from 16,666,666 to 250,000,000. This amendment was filed with the Secretary of State of Delaware on July 25, 2024.
Guidance, Outlook, and Voting Results
The filing details the final voting results for four proposals submitted at the Special Meeting. No forward-looking guidance or management commentary on future operations is included in this document.
- Issuance Proposal: Authorized issuance of shares underlying Series F-1 and G Preferred Stock and warrants (Nasdaq Rule 5635(d) compliance). Result: Approved (309,712 For; 60,094 Against; 14,116 Abstain).
- Share Increase Proposal: Increased authorized Common Stock to 250,000,000 shares. Result: Approved (819,760 For; 73,259 Against; 12,851 Abstain).
- Auditor Ratification Proposal: Ratified Morison Cogen LLP as independent auditor for fiscal year 2024. Result: Approved (1,536,758 For; 78,554 Against; 9,147 Abstain).
- Adjournment Proposal: Approved authority to adjourn the meeting if necessary. Result: Approved (1,456,064 For; 145,267 Against; 23,128 Abstain).
Contingencies and Risks: The filing notes that holders of Series F-1 and Series G Preferred Stock were not entitled to vote on the Issuance Proposal. The company references a definitive proxy statement filed on July 1, 2024, for further details on the proposals.
Investor Verification Checklist
- Verify the effective date of the Share Increase Amendment with the Delaware Secretary of State (filed July 25, 2024).
- Review the definitive proxy statement filed on July 1, 2024, for detailed terms of the Series F-1 and Series G Preferred Stock and associated warrants.
- Confirm the current number of outstanding shares versus the new authorized limit of 250,000,000.
- Check subsequent filings for the actual issuance of shares related to the approved Issuance Proposal.